SCHEMBL9740844

SCHEMBL9740844

COC(=O)/C=C/CC(C)(C)C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 3/20 0.52
HCAR2 Q8TDS4 2/20 0.52
KEAP1 Q14145 1/20 0.52
TTR P02766 1/20 0.35
APP P05067 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
TYR P14679 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
GFPT1 Q06210 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 4/20 0.33
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14488332 1.00 NFE2L2 (0.52) NFE2L2HCAR2KEAP1TTRAPP
SCHEMBL9740851 1.00 NFE2L2 (0.52) NFE2L2HCAR2KEAP1TTRAPP
SCHEMBL5911481 0.85 HCAR2 (0.46) NFE2L2HCAR2KEAP1CA12CA1
SCHEMBL5911478 0.85 HCAR2 (0.46) NFE2L2HCAR2KEAP1CA12CA1
SCHEMBL6120505 0.80 HDAC6 (0.35) CYP2C9CYP2C19
SCHEMBL15630729 0.80 HDAC6 (0.35) CYP2C9CYP2C19
SCHEMBL1716949 0.80 HCAR2 (0.50) NFE2L2HCAR2KEAP1TTRAPP
SCHEMBL1716947 0.80 HCAR2 (0.50) NFE2L2HCAR2KEAP1TTRAPP
SCHEMBL8459343 0.78 HCAR2 (0.52) HCAR2TTRCA12CA1CA2
SCHEMBL13433290 0.78 HCAR2 (0.48) NFE2L2HCAR2KEAP1TTRAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265057-A1 INHIBITORS OF PARG ARASE THERAPEUTICS INC. 2023-08-24 US disclosed
US-7553842-B2 Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases ARRAY BIOPHARMA INC. (US) 2009-06-30 US disclosed
US-5100889-A Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor E. R. SQUIBB & SONS, INC. (US) 1992-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265057-A1 INHIBITORS OF PARG PARG, PARN, PLG NFE2L2 3483/4885HCAR2 1746/4885KEAP1 2755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.